Meclofenoxate
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.000.107 |
| Chemical and physical data | |
| Formula | C12H16ClNO3 |
| Molar mass | 257.71 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Meclofenoxate (INN, BAN; brand name Lucidril, also known as centrophenoxine) is a cholinergic nootropic used as a dietary supplement.[2][3][4] It is an ester of dimethylethanolamine (DMAE) and 4-chlorophenoxyacetic acid (pCPA).
In elderly patients, meclofenoxate has been shown to improve performance on certain memory tests.[5] Meclofenoxate also increases cellular membrane phospholipids.[citation needed] It is sold in Japan and some European countries, such as Germany, Hungary, and Austria, as a prescription drug.
Side effects
[edit]Meclofenoxate is considered to be safe and high in tolerability. However, possible side effects may include, rarely, insomnia, dizziness, restlessness, muscle tremor, depression, nausea, muscle tension, and headache; these side effects may be due to overdosage and may indicate the need for the dosage to be reduced.
Research
[edit]Meclofenoxate, as well as DMAE, have been found to increase the lifespans of mice by 26.5%.[6][7]
Brand names
[edit]In addition to Lucidril, meclofenoxate has also been marketed under the brand names Amipolen, Analux, Brenal, Cellative, Centrophenoxin, Cerebron, Cerutil, Closete, Helfergin, Lucidryl, Lutiaron, Marucotol, Proserout, Proseryl, and Ropoxyl.[8] In the US, meclofenoxate is sold as a dietary supplement, although it is an unapproved drug.[4]
See also
[edit]
References
[edit]- ↑ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
- ↑ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 758–. ISBN 978-1-4757-2085-3.
- ↑ Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 636–. ISBN 978-3-88763-075-1.
- 1 2 Cohen PA, Avula B, Khan I (October 2022). "The unapproved drug centrophenoxine (meclofenoxate) in cognitive enhancement dietary supplements". Clinical Toxicology. 60 (10): 1156–1158. doi:10.1080/15563650.2022.2109485. PMID 35959800. S2CID 251516603.
- ↑ Marcer D, Hopkins SM (May 1977). "The differential effects of meclofenoxate on memory loss in the elderly". Age and Ageing. 6 (2): 123–31. doi:10.1093/ageing/6.2.123. PMID 329662.
- ↑ Donaldson T (1 January 2003). "A Brief History of Anti-aging Drugs". In Klatz R, Goldman B (eds.). The Science of Anti-aging Medicine. American Academy of Anti-Aging Med. pp. 66–. ISBN 978-0-9668937-3-1.
- ↑ Hothschild R (August 1973). "Effect of dimethylamnioethyl p-chlorophenoxyacetate on the life span of male Swiss Webster Albino mice". Experimental Gerontology. 8 (4): 177–183. doi:10.1016/0531-5565(73)90024-7. PMID 4147092.
- ↑ Zhou Y (22 October 2013). Drugs in Psychiatric Practice. Elsevier. ISBN 978-1-4831-9193-5.